{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Satraplatin",
  "nciThesaurus": {
    "casRegistry": "129580-63-8",
    "chebiId": "",
    "chemicalFormula": "C6H13N.2C2H3O2.2Cl.Pt.H3N",
    "definition": "An orally administered third generation platinum compound with potential antineoplastic activity. Satraplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in cell growth inhibition and apoptosis.",
    "fdaUniiCode": "8D7B37T28G",
    "identifier": "C1493",
    "preferredName": "Satraplatin",
    "semanticType": "Inorganic Chemical",
    "subclassOf": [
      "C1450"
    ],
    "synonyms": [
      "(OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum",
      "(OC-6-43)-bis(acetato-O)amminedichloro(cyclohexanamine)platinum",
      "BMS-182751",
      "BMY-45594",
      "JM 216",
      "JM-216",
      "Orplatna",
      "SATRAPLATIN",
      "Satraplatin",
      "platinum,bis(acetato-O)amminedichloro(cyclohexanamine)-,(OC-6-43)",
      "satraplatin"
    ]
  }
}